Cytiva investing in additional resins manufacturing operations

URLhttps://www.biopharma-reporter.com/Article/2022/07
SourceBio Pharma
Date Published07/18/2022
Author NameJane Byrne
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cytiva
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):200
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2026
Capital investment ($):1500
City reshored to:Muskegon
State(s) reshored to:MI
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredchromatography resins
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Government Incentives, Infrastructure, Lead time/Time to market, Skilled workforce availability/training
Find Reshoring Articles